These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 8980361

  • 21. Analysis of the levels of CA125, carcinoembryonic antigen, and CA19-9 in the cervical mucus for a detection of cervical adenocarcinoma.
    Fujii S, Konishi I, Nanbu Y, Nonogaki H, Kobayashi F, Sagawa N, Mori T, Endo K.
    Cancer; 1988 Aug 01; 62(3):541-7. PubMed ID: 2455590
    [Abstract] [Full Text] [Related]

  • 22. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
    Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA.
    Clin Cancer Res; 2005 May 15; 11(10):3766-72. PubMed ID: 15897574
    [Abstract] [Full Text] [Related]

  • 23. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
    Kobayashi H, Sumimoto K, Terao T, Kawashima Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct 15; 41(10):1501-6. PubMed ID: 2573640
    [Abstract] [Full Text] [Related]

  • 24. Metastatic adenocarcinoma of an unknown primary site. A comparison of the relative contributions of morphology, minimal essential clinical data and CEA immunostaining status.
    Sheahan K, O'Keane JC, Abramowitz A, Carlson JA, Burke B, Gottlieb LS, O'Brien MJ.
    Am J Clin Pathol; 1993 Jun 15; 99(6):729-35. PubMed ID: 8322709
    [Abstract] [Full Text] [Related]

  • 25. Monoclonal anti-CEA antibodies in the discrimination between primary pulmonary adenocarcinoma and colon carcinoma metastatic to the lung.
    Ghoneim AH, Brisson ML, Fuks A, Mobasher AA, Kreisman H.
    Mod Pathol; 1990 Sep 15; 3(5):613-8. PubMed ID: 2235987
    [Abstract] [Full Text] [Related]

  • 26. Distribution of colon-ovarian tumor antigen in adenocarcinomas. An immunohistochemical study of 501 cases.
    Loy TS, Darkow GV.
    Am J Clin Pathol; 1993 Feb 15; 99(2):207-10. PubMed ID: 7679875
    [Abstract] [Full Text] [Related]

  • 27. Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma.
    Chen Z, Wang Y, Fang M.
    Cancer Med; 2020 Feb 15; 9(4):1392-1399. PubMed ID: 31881123
    [Abstract] [Full Text] [Related]

  • 28. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
    Zhang J, Wei Q, Dong D, Ren L.
    Clin Chim Acta; 2021 Dec 15; 523():19-25. PubMed ID: 34454906
    [Abstract] [Full Text] [Related]

  • 29. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K, Karaki K, Watanabe K, Tsuda H, Konishi F.
    Rinsho Byori; 1993 Oct 15; 41(10):1108-15. PubMed ID: 8254956
    [Abstract] [Full Text] [Related]

  • 30. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K.
    Pathol Int; 2007 Apr 15; 57(4):190-9. PubMed ID: 17316414
    [Abstract] [Full Text] [Related]

  • 31. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
    Wen Z, Huang Y, Ling Z, Chen J, Wei X, Su R, Tang Z, Wen Z, Deng Y, Hu Z.
    Dis Markers; 2020 Apr 15; 2020():4716793. PubMed ID: 33488842
    [Abstract] [Full Text] [Related]

  • 32. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies.
    Sheahan K, O'Brien MJ, Burke B, Dervan PA, O'Keane JC, Gottlieb LS, Zamcheck N.
    Am J Clin Pathol; 1990 Aug 15; 94(2):157-64. PubMed ID: 1695478
    [Abstract] [Full Text] [Related]

  • 33. Reactivity of B72.3 with adenocarcinomas. An immunohistochemical study of 476 cases.
    Loy TS, Nashelsky MB.
    Cancer; 1993 Oct 15; 72(8):2495-8. PubMed ID: 8402466
    [Abstract] [Full Text] [Related]

  • 34. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
    Feng M, Zhu J, Liang L, Zeng N, Wu Y, Wan C, Shen Y, Wen F.
    Int J Clin Oncol; 2017 Apr 15; 22(2):283-290. PubMed ID: 27990560
    [Abstract] [Full Text] [Related]

  • 35. [Immunohistochemical flow chart to differentiate between primary adenocarcinoma and the most frequent extragynecological metastases in the ovary].
    Pires Y, Andrade L, Cuello M, Chuaqui R.
    Rev Med Chil; 2002 Nov 15; 130(11):1232-40. PubMed ID: 12587505
    [Abstract] [Full Text] [Related]

  • 36. The immunohistochemical discrimination of endometrioid adenocarcinomas.
    Dabbs DJ, Sturtz K, Zaino RJ.
    Hum Pathol; 1996 Feb 15; 27(2):172-7. PubMed ID: 8617459
    [Abstract] [Full Text] [Related]

  • 37. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y, Imoto S, Kasakura S.
    Rinsho Byori; 1995 Jul 15; 43(7):696-702. PubMed ID: 7674542
    [Abstract] [Full Text] [Related]

  • 38. Monoclonal antibody SM047 as an immunohistochemical marker of ovarian adenocarcinoma.
    McCluggage WG, Maxwell P, Veenstra H, Fick CE, Laeng RH, Tiltman AJ.
    Histopathology; 2001 Jun 15; 38(6):542-9. PubMed ID: 11422498
    [Abstract] [Full Text] [Related]

  • 39. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
    Dai H, Liu J, Liang L, Ban C, Jiang J, Liu Y, Ye Q, Wang C.
    Respirology; 2014 Jul 15; 19(5):707-13. PubMed ID: 24903079
    [Abstract] [Full Text] [Related]

  • 40. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma.
    Loy TS, Calaluce RD, Keeney GL.
    Mod Pathol; 1996 Nov 15; 9(11):1040-4. PubMed ID: 8933513
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.